Empire Prevent

The Empire Prevent trial program marks the first step towards elucidating the potential of SGLT2 inhibition for HF prevention 🫀🫀 Further reading: pubmed.ncbi.nlm.nih.gov/38365073/ @CardResearchOuh @HGHHjerte @RigsHeart @jhempelheart @FuchsAndersen @mortschou

🩷🩵First patient follow-up at Odense University Hospital @CardResearchOuh ☑️🚴‍♀️🫀💊 @EmpirePrevent @FuchsAndersen @mortschou @jhempelheart @RigsHeart @SDCOdense @HGHHjerte

🩵🩷Empire Prevent on track! 🩵🩷 58% of target population enrolled at @CardReseachOUH & @HGHHjerte Collaboration with @SDCOdense & @RigsHeart

Empire Prevent 🩵🩷 includes patients in Odense @CardResearchOuh and Copenhagen @HGHHjerte. We greatly appreciate our collaboration with @SDCOdense and @RigsHeart 🩵🩷

Patient #100 randomized in Empire Prevent Empagliflozin to elderly and obese patients with cardiovascular disease (Empire Prevent): a randomized controlled trial. Collaboration between @CardResearchOuh and @HGHHjerte.